P25.03: Effect of IVF/ICSI on second trimester screening markers

Abstract

22nd World Congress on Ultrasound in Obstetrics and GynecologyPoster abstracts and extracardiac sonographic survey was performed. During the study period the recommendation of fetal invasive testing relied on well-accepted indications and not solely on the presence of ARSA. Results: ARSA was detected in 64/15.352 fetuses examined (0.4%). The mean gestational age at diagnosis was 21.9 ± 2.9 weeks. 8/64 fetuses had an abnormal karyotype (7 T21, 1 22q11 microdeletion) and one had sonographic suspicion of trisomy 18 but the parents refused fetal karyotype analysis. In the same period, 72 fetuses were diagnosed of T21 and without ARSA. The prevalence of ARSA in fetuses with T21 was higher than in those without this aneuploidy (7/79=9% vs. 57/15273=0.4%). ARSA was an isolated finding in 43/57 (75.4%) fetuses without T21, and in 2/7 patients with T21 (28.6%). In one of these 2 cases the diagnosis of T21 was made postnatally while the other was diagnosed by amniocentesis indicated because advanced maternal age (40 years). In these two cases the results of the first trimester combined screening for aneuploidies was not available. The likelihood ratio for T21 when isolated ARSA is detected was 9 (95% CI: 1.8-41.9). Conclusions: The prevalence of ARSA is higher in T21 fetuses than in fetuses without this aneuploidy. ARSA may be an isolated finding in T21 fetuses; therefore, fetal karyotyping should be recommended whenever ARSA is diagnosed, especially if the results of first trimester combined screening are not available. P25.03Effect of IVF/ICSI on second trimester screening markers